[Antineoplastic and toxic effects of blastolysin in the treatment of spontaneous mammary cancer in dogs].
The anticancer activity and toxicity of blastolysin were studied in 13 dogs with mammary cancer using two different schedules. The agent was given 5 times in a dose of 2.5-10 mg/kg with a 72 h interval (the first schedule) and 10 times in a dose of 0.4-1.7 mg/kg in 24 h (the second schedule). The first schedule exhibited the highest anticancer effect with the least toxicity. Blastolysin was found to depress erythropoiesis.
D000818:Animals; D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D004285:Dogs; D004920:Erythropoiesis / Q000187:drug effects; D005260:Female; D006020:Glycopeptides / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D006020:Glycopeptides; C025182:blastolysin
Protivoopukholevoe i toksicheskoe deĭstvie blastolizina pri terapii spontannogo raka molochnykh zhelez u sobak.